| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Borrelia burgdorferi | 29 | 2025 | 93 | 9.230 |
Why?
|
| Bacterial Proteins | 21 | 2025 | 741 | 5.020 |
Why?
|
| Lyme Disease | 21 | 2025 | 123 | 4.090 |
Why?
|
| Veterans | 8 | 2026 | 770 | 2.870 |
Why?
|
| Employment | 4 | 2026 | 132 | 2.640 |
Why?
|
| Gene Expression Regulation, Bacterial | 10 | 2020 | 146 | 2.610 |
Why?
|
| Bacterial Outer Membrane Proteins | 11 | 2015 | 127 | 2.560 |
Why?
|
| Mental Disorders | 5 | 2026 | 827 | 2.100 |
Why?
|
| DNA-Binding Proteins | 9 | 2025 | 1226 | 1.970 |
Why?
|
| RNA-Binding Proteins | 4 | 2024 | 446 | 1.810 |
Why?
|
| Lipoproteins | 8 | 2015 | 85 | 1.750 |
Why?
|
| DNA, Bacterial | 9 | 2025 | 262 | 1.740 |
Why?
|
| Employment, Supported | 2 | 2025 | 21 | 1.680 |
Why?
|
| Substance-Related Disorders | 3 | 2026 | 758 | 1.500 |
Why?
|
| Antigens, Neoplasm | 15 | 2024 | 134 | 1.440 |
Why?
|
| Rehabilitation, Vocational | 3 | 2025 | 32 | 1.230 |
Why?
|
| Antigens, Bacterial | 6 | 2015 | 202 | 1.190 |
Why?
|
| Unemployment | 2 | 2026 | 19 | 1.150 |
Why?
|
| Gene Expression Profiling | 13 | 2020 | 799 | 1.070 |
Why?
|
| RNA, Bacterial | 3 | 2018 | 73 | 1.040 |
Why?
|
| Borrelia | 6 | 2025 | 31 | 1.000 |
Why?
|
| Ticks | 5 | 2020 | 36 | 0.960 |
Why?
|
| Substance Abuse Detection | 1 | 2026 | 39 | 0.930 |
Why?
|
| Chromatography, Affinity | 1 | 2025 | 52 | 0.910 |
Why?
|
| United States Department of Veterans Affairs | 4 | 2023 | 549 | 0.890 |
Why?
|
| DNA | 3 | 2025 | 853 | 0.820 |
Why?
|
| Cyclic GMP | 1 | 2024 | 33 | 0.820 |
Why?
|
| Laminin | 3 | 2009 | 81 | 0.820 |
Why?
|
| Mass Spectrometry | 1 | 2025 | 296 | 0.810 |
Why?
|
| Psychotherapy | 2 | 2022 | 102 | 0.750 |
Why?
|
| Peptides | 8 | 2024 | 593 | 0.720 |
Why?
|
| Terminology as Topic | 3 | 2025 | 145 | 0.710 |
Why?
|
| Ovarian Neoplasms | 5 | 2023 | 170 | 0.700 |
Why?
|
| Spirochaetales | 2 | 2020 | 6 | 0.700 |
Why?
|
| Molecular Sequence Data | 20 | 2015 | 1980 | 0.680 |
Why?
|
| Melanoma | 5 | 2023 | 335 | 0.660 |
Why?
|
| Sequence Analysis, RNA | 4 | 2016 | 182 | 0.650 |
Why?
|
| Humans | 75 | 2026 | 65831 | 0.640 |
Why?
|
| Membrane Proteins | 6 | 2021 | 926 | 0.630 |
Why?
|
| RNA | 2 | 2023 | 427 | 0.620 |
Why?
|
| Community Integration | 1 | 2020 | 7 | 0.620 |
Why?
|
| Genes, Bacterial | 5 | 2020 | 115 | 0.610 |
Why?
|
| Immunotherapy | 7 | 2024 | 274 | 0.600 |
Why?
|
| Base Sequence | 16 | 2015 | 1332 | 0.590 |
Why?
|
| Genes, Neoplasm | 2 | 2011 | 25 | 0.590 |
Why?
|
| Mutation | 12 | 2020 | 2675 | 0.570 |
Why?
|
| Transcriptome | 2 | 2020 | 408 | 0.560 |
Why?
|
| Fibronectins | 2 | 2009 | 44 | 0.560 |
Why?
|
| Gene Regulatory Networks | 3 | 2018 | 160 | 0.540 |
Why?
|
| RNA, Messenger | 11 | 2024 | 1583 | 0.540 |
Why?
|
| Superoxide Dismutase | 1 | 2019 | 223 | 0.530 |
Why?
|
| Leptospira interrogans | 2 | 2025 | 3 | 0.500 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2020 | 588 | 0.480 |
Why?
|
| Public Health | 1 | 2018 | 188 | 0.480 |
Why?
|
| Amino Acid Sequence | 12 | 2020 | 1590 | 0.480 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2021 | 406 | 0.470 |
Why?
|
| Prophages | 2 | 2013 | 6 | 0.470 |
Why?
|
| Borrelia burgdorferi Group | 3 | 2019 | 30 | 0.460 |
Why?
|
| Phylogeny | 5 | 2025 | 399 | 0.460 |
Why?
|
| Animals | 34 | 2025 | 21492 | 0.450 |
Why?
|
| Plasmids | 3 | 2013 | 294 | 0.440 |
Why?
|
| Patient Safety | 1 | 2018 | 281 | 0.440 |
Why?
|
| Genetic Variation | 4 | 2013 | 395 | 0.420 |
Why?
|
| DNA Copy Number Variations | 2 | 2012 | 73 | 0.420 |
Why?
|
| Ixodes | 3 | 2014 | 35 | 0.420 |
Why?
|
| Doxycycline | 2 | 2025 | 47 | 0.410 |
Why?
|
| Mice | 21 | 2023 | 11185 | 0.400 |
Why?
|
| Operator Regions, Genetic | 2 | 2010 | 6 | 0.390 |
Why?
|
| Female | 34 | 2026 | 34420 | 0.390 |
Why?
|
| Host-Pathogen Interactions | 3 | 2020 | 279 | 0.390 |
Why?
|
| Precision Medicine | 3 | 2024 | 134 | 0.380 |
Why?
|
| Cancer Vaccines | 4 | 2024 | 51 | 0.380 |
Why?
|
| Proteogenomics | 2 | 2024 | 2 | 0.380 |
Why?
|
| Proteomics | 3 | 2025 | 299 | 0.370 |
Why?
|
| Genome, Human | 7 | 2016 | 238 | 0.360 |
Why?
|
| United States | 6 | 2026 | 8186 | 0.350 |
Why?
|
| Exome | 6 | 2020 | 69 | 0.340 |
Why?
|
| Osteochondrodysplasias | 3 | 2016 | 12 | 0.340 |
Why?
|
| Chromosomes, Human, X | 3 | 2008 | 35 | 0.330 |
Why?
|
| Sequence Alignment | 6 | 2019 | 302 | 0.330 |
Why?
|
| Male | 24 | 2026 | 31403 | 0.320 |
Why?
|
| Adult | 13 | 2026 | 17575 | 0.320 |
Why?
|
| Signal Transduction | 5 | 2020 | 3170 | 0.320 |
Why?
|
| Protein Binding | 5 | 2024 | 1638 | 0.320 |
Why?
|
| Neoplasms | 4 | 2024 | 1377 | 0.310 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2023 | 679 | 0.300 |
Why?
|
| Dendritic Cells | 4 | 2019 | 534 | 0.290 |
Why?
|
| Software | 3 | 2024 | 401 | 0.290 |
Why?
|
| Cell Line, Tumor | 12 | 2022 | 1573 | 0.290 |
Why?
|
| Protein Interaction Mapping | 1 | 2009 | 69 | 0.290 |
Why?
|
| Mice, Inbred C3H | 2 | 2019 | 173 | 0.280 |
Why?
|
| Computational Biology | 9 | 2016 | 369 | 0.280 |
Why?
|
| Expressed Sequence Tags | 8 | 2007 | 28 | 0.270 |
Why?
|
| Histocompatibility Antigens Class I | 4 | 2024 | 143 | 0.270 |
Why?
|
| Endostatins | 1 | 2007 | 4 | 0.270 |
Why?
|
| Middle Aged | 11 | 2026 | 18498 | 0.270 |
Why?
|
| Breast Neoplasms | 5 | 2022 | 1235 | 0.270 |
Why?
|
| Anti-Bacterial Agents | 2 | 2025 | 808 | 0.260 |
Why?
|
| Transcription, Genetic | 8 | 2021 | 911 | 0.260 |
Why?
|
| Genomics | 4 | 2009 | 387 | 0.260 |
Why?
|
| Sequence Homology, Amino Acid | 4 | 2010 | 365 | 0.260 |
Why?
|
| Complement System Proteins | 1 | 2007 | 110 | 0.250 |
Why?
|
| Complement Factor H | 1 | 2008 | 120 | 0.250 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 2023 | 282 | 0.250 |
Why?
|
| Protein Structure, Tertiary | 4 | 2013 | 672 | 0.240 |
Why?
|
| Growth Disorders | 2 | 2018 | 31 | 0.240 |
Why?
|
| Testis | 4 | 2008 | 160 | 0.230 |
Why?
|
| Neoplasm Proteins | 5 | 2019 | 286 | 0.230 |
Why?
|
| Social Support | 2 | 2026 | 394 | 0.230 |
Why?
|
| Self-Control | 1 | 2025 | 10 | 0.230 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2025 | 91 | 0.220 |
Why?
|
| Bone Diseases, Developmental | 2 | 2016 | 7 | 0.220 |
Why?
|
| Peer Group | 1 | 2026 | 114 | 0.220 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2015 | 449 | 0.220 |
Why?
|
| Mice, Inbred BALB C | 4 | 2009 | 869 | 0.210 |
Why?
|
| Brain Neoplasms | 2 | 2021 | 322 | 0.210 |
Why?
|
| Databases, Genetic | 4 | 2011 | 91 | 0.210 |
Why?
|
| Conserved Sequence | 3 | 2013 | 173 | 0.210 |
Why?
|
| Craniofacial Abnormalities | 2 | 2015 | 23 | 0.210 |
Why?
|
| Recombination, Genetic | 3 | 2012 | 256 | 0.210 |
Why?
|
| Abnormalities, Multiple | 2 | 2015 | 54 | 0.210 |
Why?
|
| Rural Population | 1 | 2026 | 225 | 0.200 |
Why?
|
| Protein Domains | 1 | 2024 | 155 | 0.190 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2023 | 61 | 0.190 |
Why?
|
| T-Lymphocytes | 5 | 2023 | 1012 | 0.190 |
Why?
|
| Amoxicillin | 1 | 2022 | 8 | 0.190 |
Why?
|
| Genes, T-Cell Receptor alpha | 2 | 2012 | 5 | 0.190 |
Why?
|
| Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 2 | 2012 | 6 | 0.190 |
Why?
|
| Comorbidity | 1 | 2026 | 1122 | 0.190 |
Why?
|
| Vaccines | 1 | 2023 | 97 | 0.180 |
Why?
|
| Access to Information | 1 | 2022 | 31 | 0.180 |
Why?
|
| Colorectal Neoplasms | 2 | 2019 | 290 | 0.180 |
Why?
|
| Sequence Analysis, DNA | 5 | 2016 | 417 | 0.180 |
Why?
|
| Prevalence | 1 | 2026 | 1453 | 0.170 |
Why?
|
| Head and Neck Neoplasms | 1 | 2022 | 166 | 0.170 |
Why?
|
| Promoter Regions, Genetic | 2 | 2019 | 690 | 0.170 |
Why?
|
| Nuclear Proteins | 3 | 2021 | 793 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 3 | 2009 | 514 | 0.170 |
Why?
|
| Surveys and Questionnaires | 2 | 2026 | 2790 | 0.170 |
Why?
|
| Androgen-Insensitivity Syndrome | 1 | 2020 | 1 | 0.170 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2020 | 10 | 0.160 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2012 | 518 | 0.160 |
Why?
|
| Histocompatibility Antigens | 1 | 2021 | 107 | 0.160 |
Why?
|
| Receptors, Cell Surface | 1 | 2003 | 432 | 0.160 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2025 | 273 | 0.160 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 70 | 0.160 |
Why?
|
| Open Reading Frames | 2 | 2013 | 84 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2007 | 542 | 0.160 |
Why?
|
| Health Services Accessibility | 1 | 2026 | 603 | 0.160 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2020 | 316 | 0.160 |
Why?
|
| Cell Adhesion Molecules | 2 | 2014 | 95 | 0.160 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 667 | 0.160 |
Why?
|
| Life History Traits | 1 | 2019 | 2 | 0.150 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2019 | 5 | 0.150 |
Why?
|
| Receptors, Androgen | 1 | 2020 | 88 | 0.150 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2021 | 179 | 0.150 |
Why?
|
| Classification | 1 | 2019 | 14 | 0.150 |
Why?
|
| Borrelia Infections | 1 | 2019 | 12 | 0.150 |
Why?
|
| Immunotherapy, Active | 1 | 2019 | 3 | 0.150 |
Why?
|
| Relapsing Fever | 1 | 2019 | 16 | 0.150 |
Why?
|
| Immune Evasion | 1 | 2020 | 71 | 0.150 |
Why?
|
| Organoids | 1 | 2019 | 44 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 92 | 0.150 |
Why?
|
| Sepsis | 1 | 2003 | 309 | 0.150 |
Why?
|
| Glioblastoma | 1 | 2021 | 161 | 0.150 |
Why?
|
| Neovascularization, Pathologic | 2 | 2021 | 140 | 0.140 |
Why?
|
| Trans-Activators | 1 | 2021 | 321 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 129 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 50 | 0.140 |
Why?
|
| Transformation, Genetic | 1 | 1998 | 31 | 0.140 |
Why?
|
| Military Personnel | 1 | 2020 | 111 | 0.140 |
Why?
|
| Operon | 1 | 2018 | 31 | 0.140 |
Why?
|
| Species Specificity | 2 | 2013 | 344 | 0.140 |
Why?
|
| Glycerol | 1 | 2018 | 34 | 0.140 |
Why?
|
| Puberty, Delayed | 1 | 2018 | 3 | 0.140 |
Why?
|
| Aspirin | 1 | 2019 | 172 | 0.140 |
Why?
|
| Hypogonadism | 1 | 2018 | 15 | 0.140 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2020 | 235 | 0.140 |
Why?
|
| Inflammation | 2 | 2023 | 1198 | 0.130 |
Why?
|
| Virulence Factors | 1 | 2018 | 86 | 0.130 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2019 | 128 | 0.130 |
Why?
|
| Genes, Recessive | 2 | 2015 | 51 | 0.130 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2018 | 169 | 0.130 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2018 | 186 | 0.130 |
Why?
|
| Binding Sites | 2 | 2010 | 922 | 0.130 |
Why?
|
| Atenolol | 1 | 2016 | 9 | 0.120 |
Why?
|
| Mental Health | 1 | 2020 | 364 | 0.120 |
Why?
|
| Isoproterenol | 1 | 2016 | 38 | 0.120 |
Why?
|
| Oxidoreductases | 1 | 2016 | 61 | 0.120 |
Why?
|
| Models, Genetic | 2 | 2015 | 267 | 0.120 |
Why?
|
| Oxo-Acid-Lyases | 1 | 2016 | 9 | 0.120 |
Why?
|
| Bone Remodeling | 1 | 2016 | 25 | 0.120 |
Why?
|
| Brain | 2 | 2016 | 1672 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 712 | 0.120 |
Why?
|
| Sialic Acids | 1 | 2016 | 33 | 0.120 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2015 | 18 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 354 | 0.120 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2009 | 185 | 0.120 |
Why?
|
| Bone Density | 1 | 2016 | 142 | 0.110 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2016 | 162 | 0.110 |
Why?
|
| Tooth Abnormalities | 1 | 2015 | 2 | 0.110 |
Why?
|
| Hip Dislocation, Congenital | 1 | 2015 | 3 | 0.110 |
Why?
|
| ATP-Dependent Proteases | 1 | 2015 | 7 | 0.110 |
Why?
|
| Eye Abnormalities | 1 | 2015 | 21 | 0.110 |
Why?
|
| Antibodies, Bacterial | 1 | 2015 | 181 | 0.110 |
Why?
|
| Developmental Disabilities | 1 | 2016 | 119 | 0.110 |
Why?
|
| Neoplasm Grading | 3 | 2021 | 102 | 0.110 |
Why?
|
| Astrocytoma | 1 | 2014 | 14 | 0.100 |
Why?
|
| Heartwater Disease | 1 | 2014 | 1 | 0.100 |
Why?
|
| Semliki forest virus | 1 | 2014 | 1 | 0.100 |
Why?
|
| Ehrlichia ruminantium | 1 | 2014 | 1 | 0.100 |
Why?
|
| Alphavirus Infections | 1 | 2014 | 1 | 0.100 |
Why?
|
| Disease Models, Animal | 4 | 2025 | 2329 | 0.100 |
Why?
|
| Heart | 1 | 2016 | 298 | 0.100 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2014 | 8 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2016 | 344 | 0.100 |
Why?
|
| Gene Silencing | 2 | 2021 | 439 | 0.100 |
Why?
|
| NFATC Transcription Factors | 1 | 2014 | 20 | 0.100 |
Why?
|
| Hirschsprung Disease | 1 | 2014 | 8 | 0.100 |
Why?
|
| CD8 Antigens | 1 | 2014 | 53 | 0.100 |
Why?
|
| Mitochondrial Proteins | 1 | 2015 | 110 | 0.100 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2014 | 75 | 0.100 |
Why?
|
| Placenta | 1 | 2014 | 73 | 0.100 |
Why?
|
| Plasminogen | 1 | 2013 | 8 | 0.100 |
Why?
|
| Hyperostosis, Cortical, Congenital | 1 | 2013 | 1 | 0.100 |
Why?
|
| 5' Flanking Region | 1 | 2013 | 10 | 0.100 |
Why?
|
| Hair | 1 | 2014 | 81 | 0.100 |
Why?
|
| Dwarfism | 1 | 2013 | 16 | 0.100 |
Why?
|
| Hypoparathyroidism | 1 | 2013 | 8 | 0.100 |
Why?
|
| Hypocalcemia | 1 | 2013 | 19 | 0.100 |
Why?
|
| Immunity, Cellular | 1 | 2014 | 170 | 0.100 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2012 | 9 | 0.100 |
Why?
|
| Receptors, Virus | 1 | 2013 | 73 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2014 | 377 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2014 | 344 | 0.090 |
Why?
|
| CTLA-4 Antigen | 1 | 2012 | 73 | 0.090 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 565 | 0.090 |
Why?
|
| Monocytes | 1 | 2015 | 362 | 0.090 |
Why?
|
| Thymocytes | 1 | 2012 | 23 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 737 | 0.090 |
Why?
|
| Zebrafish | 1 | 2016 | 374 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 21 | 2 | 2002 | 30 | 0.090 |
Why?
|
| Mice, Transgenic | 3 | 2015 | 1292 | 0.090 |
Why?
|
| DNA, Single-Stranded | 1 | 2013 | 109 | 0.090 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2011 | 5 | 0.090 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2011 | 16 | 0.090 |
Why?
|
| Cell Movement | 1 | 2014 | 484 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2011 | 46 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2012 | 297 | 0.090 |
Why?
|
| Cell Nucleolus | 1 | 2012 | 71 | 0.090 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2012 | 146 | 0.090 |
Why?
|
| Cell Differentiation | 2 | 2014 | 1391 | 0.090 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2011 | 21 | 0.080 |
Why?
|
| Karyotyping | 1 | 2011 | 48 | 0.080 |
Why?
|
| Blotting, Western | 2 | 2015 | 611 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2011 | 33 | 0.080 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2019 | 111 | 0.080 |
Why?
|
| Gene Expression | 2 | 2005 | 856 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2011 | 161 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 223 | 0.080 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 223 | 0.080 |
Why?
|
| Binding, Competitive | 1 | 2010 | 96 | 0.080 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 39 | 0.080 |
Why?
|
| DNA Primers | 2 | 2007 | 302 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2016 | 714 | 0.080 |
Why?
|
| Models, Biological | 1 | 2015 | 1193 | 0.080 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2011 | 238 | 0.080 |
Why?
|
| Genotype | 3 | 2020 | 676 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2011 | 307 | 0.080 |
Why?
|
| Bacterial Adhesion | 1 | 2009 | 65 | 0.070 |
Why?
|
| Linkage Disequilibrium | 1 | 2009 | 47 | 0.070 |
Why?
|
| Gene Rearrangement | 1 | 2009 | 41 | 0.070 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2009 | 89 | 0.070 |
Why?
|
| Collagen | 1 | 2009 | 135 | 0.070 |
Why?
|
| Testicular Neoplasms | 1 | 2008 | 34 | 0.070 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2009 | 252 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2022 | 593 | 0.070 |
Why?
|
| Immunoblotting | 2 | 2015 | 202 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2015 | 233 | 0.070 |
Why?
|
| Tissue Distribution | 2 | 2006 | 292 | 0.070 |
Why?
|
| User-Computer Interface | 1 | 2009 | 127 | 0.070 |
Why?
|
| Virus Integration | 1 | 2008 | 33 | 0.070 |
Why?
|
| Protein Multimerization | 1 | 2009 | 181 | 0.070 |
Why?
|
| Nucleic Acid Conformation | 1 | 2009 | 241 | 0.070 |
Why?
|
| Lentivirus | 1 | 2008 | 64 | 0.070 |
Why?
|
| Proteins | 2 | 2004 | 764 | 0.070 |
Why?
|
| Internet | 2 | 2009 | 472 | 0.070 |
Why?
|
| Pentanes | 1 | 2007 | 4 | 0.060 |
Why?
|
| Pan troglodytes | 1 | 2007 | 33 | 0.060 |
Why?
|
| Biomarkers, Tumor | 2 | 2008 | 527 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2011 | 411 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2026 | 2739 | 0.060 |
Why?
|
| Ligands | 1 | 2008 | 414 | 0.060 |
Why?
|
| Child | 4 | 2020 | 4651 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2016 | 2089 | 0.060 |
Why?
|
| Temperature | 1 | 2007 | 317 | 0.060 |
Why?
|
| Alcohol Amnestic Disorder | 1 | 2005 | 1 | 0.060 |
Why?
|
| Temperance | 1 | 2005 | 13 | 0.060 |
Why?
|
| Infant | 3 | 2016 | 1718 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2007 | 465 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2007 | 401 | 0.060 |
Why?
|
| Macaca | 1 | 2025 | 30 | 0.060 |
Why?
|
| Gastrointestinal Tract | 1 | 2007 | 187 | 0.060 |
Why?
|
| Memory, Short-Term | 1 | 2005 | 67 | 0.060 |
Why?
|
| Mice, Knockout | 3 | 2016 | 2168 | 0.050 |
Why?
|
| Meiosis | 1 | 2005 | 80 | 0.050 |
Why?
|
| Macaca mulatta | 1 | 2006 | 263 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2025 | 107 | 0.050 |
Why?
|
| Evolution, Molecular | 1 | 2007 | 351 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2007 | 506 | 0.050 |
Why?
|
| Adolescent | 4 | 2016 | 6367 | 0.050 |
Why?
|
| Epigenesis, Genetic | 2 | 2021 | 408 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2018 | 2651 | 0.050 |
Why?
|
| Toll-Like Receptor 10 | 1 | 2003 | 1 | 0.050 |
Why?
|
| RGS Proteins | 1 | 2003 | 3 | 0.050 |
Why?
|
| Neuropsychological Tests | 1 | 2005 | 420 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2003 | 23 | 0.050 |
Why?
|
| Adoptive Transfer | 1 | 2023 | 145 | 0.050 |
Why?
|
| Clone Cells | 1 | 2023 | 111 | 0.050 |
Why?
|
| Cell Line | 3 | 2015 | 2031 | 0.050 |
Why?
|
| Synteny | 1 | 2002 | 24 | 0.050 |
Why?
|
| Dentistry | 1 | 2022 | 8 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 387 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2006 | 745 | 0.050 |
Why?
|
| United Kingdom | 1 | 2022 | 86 | 0.050 |
Why?
|
| Proteome | 1 | 2003 | 153 | 0.050 |
Why?
|
| 3' Flanking Region | 1 | 2002 | 8 | 0.050 |
Why?
|
| Alternative Splicing | 1 | 2003 | 140 | 0.050 |
Why?
|
| Genetic Heterogeneity | 1 | 2002 | 21 | 0.050 |
Why?
|
| Chromatin | 2 | 2021 | 643 | 0.050 |
Why?
|
| Alcoholism | 1 | 2005 | 329 | 0.050 |
Why?
|
| Aged | 4 | 2026 | 15145 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 2010 | 426 | 0.040 |
Why?
|
| Bias | 1 | 2022 | 117 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 183 | 0.040 |
Why?
|
| DNA, Complementary | 3 | 2009 | 165 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 174 | 0.040 |
Why?
|
| Chemokine CCL5 | 1 | 2021 | 32 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2008 | 930 | 0.040 |
Why?
|
| Alleles | 2 | 2014 | 455 | 0.040 |
Why?
|
| Machine Learning | 1 | 2023 | 197 | 0.040 |
Why?
|
| Endopeptidase K | 1 | 2001 | 4 | 0.040 |
Why?
|
| Immune Sera | 1 | 2001 | 35 | 0.040 |
Why?
|
| Toll-Like Receptors | 1 | 2003 | 434 | 0.040 |
Why?
|
| Peptide Library | 1 | 2021 | 33 | 0.040 |
Why?
|
| Arthropod Vectors | 1 | 2020 | 3 | 0.040 |
Why?
|
| Young Adult | 3 | 2016 | 4882 | 0.040 |
Why?
|
| Sexual Development | 1 | 2020 | 4 | 0.040 |
Why?
|
| Interferons | 1 | 2021 | 74 | 0.040 |
Why?
|
| Vaccination | 1 | 2023 | 388 | 0.040 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2020 | 7 | 0.040 |
Why?
|
| Platelet Aggregation | 1 | 2020 | 24 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 143 | 0.040 |
Why?
|
| Cattle | 1 | 2021 | 320 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2016 | 1438 | 0.040 |
Why?
|
| Chromosome Mapping | 3 | 2008 | 297 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 238 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2019 | 15 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 3506 | 0.040 |
Why?
|
| Databases, Protein | 1 | 2020 | 45 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 27 | 0.040 |
Why?
|
| Cytokines | 2 | 2015 | 965 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2021 | 234 | 0.040 |
Why?
|
| Adaptation, Physiological | 1 | 2020 | 132 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2019 | 128 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 39 | 0.040 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2019 | 83 | 0.040 |
Why?
|
| DNA Damage | 1 | 2021 | 298 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 64 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 899 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 1998 | 13 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 375 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2021 | 488 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 502 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 198 | 0.030 |
Why?
|
| Finland | 1 | 2018 | 21 | 0.030 |
Why?
|
| HIV-1 | 1 | 2003 | 710 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2018 | 84 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 553 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2018 | 61 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2016 | 2194 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2019 | 576 | 0.030 |
Why?
|
| Pregnancy | 2 | 2015 | 2401 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2011 | 211 | 0.030 |
Why?
|
| Gene Ontology | 1 | 2016 | 38 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2016 | 185 | 0.030 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2016 | 20 | 0.030 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2016 | 65 | 0.030 |
Why?
|
| Wnt Proteins | 1 | 2016 | 104 | 0.030 |
Why?
|
| Age of Onset | 1 | 2016 | 174 | 0.030 |
Why?
|
| Epitope Mapping | 1 | 2015 | 52 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2015 | 40 | 0.030 |
Why?
|
| Pelger-Huet Anomaly | 1 | 2015 | 3 | 0.030 |
Why?
|
| Optic Atrophy | 1 | 2015 | 6 | 0.030 |
Why?
|
| Embryo, Nonmammalian | 1 | 2016 | 184 | 0.030 |
Why?
|
| Switzerland | 1 | 2015 | 17 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2015 | 97 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2016 | 312 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2016 | 152 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2015 | 77 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 2500 | 0.030 |
Why?
|
| Retina | 1 | 2015 | 135 | 0.030 |
Why?
|
| 12E7 Antigen | 1 | 2014 | 2 | 0.030 |
Why?
|
| Databases, Nucleic Acid | 2 | 2005 | 9 | 0.030 |
Why?
|
| Collagen Type XI | 1 | 2014 | 1 | 0.030 |
Why?
|
| Immune System | 1 | 2015 | 133 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2016 | 423 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2015 | 157 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 420 | 0.030 |
Why?
|
| Complement C5 | 1 | 2013 | 8 | 0.020 |
Why?
|
| Pedigree | 1 | 2014 | 193 | 0.020 |
Why?
|
| Fibrinolysin | 1 | 2013 | 6 | 0.020 |
Why?
|
| Algorithms | 2 | 2012 | 1060 | 0.020 |
Why?
|
| Complement C3b | 1 | 2013 | 18 | 0.020 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2013 | 13 | 0.020 |
Why?
|
| Homeostasis | 1 | 2016 | 383 | 0.020 |
Why?
|
| Coinfection | 1 | 2014 | 59 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2014 | 257 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 178 | 0.020 |
Why?
|
| Organ Specificity | 2 | 2005 | 201 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2014 | 200 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2013 | 44 | 0.020 |
Why?
|
| Antigenic Variation | 1 | 2012 | 7 | 0.020 |
Why?
|
| Self Tolerance | 1 | 2012 | 20 | 0.020 |
Why?
|
| Complementarity Determining Regions | 1 | 2012 | 33 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 120 | 0.020 |
Why?
|
| Heterozygote | 1 | 2013 | 175 | 0.020 |
Why?
|
| Breast | 2 | 2006 | 194 | 0.020 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2012 | 60 | 0.020 |
Why?
|
| Normal Distribution | 1 | 2012 | 17 | 0.020 |
Why?
|
| Virus Replication | 1 | 2014 | 323 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 65 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2013 | 190 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2012 | 112 | 0.020 |
Why?
|
| Desmocollins | 1 | 2011 | 2 | 0.020 |
Why?
|
| Receptors, LDL | 1 | 2011 | 35 | 0.020 |
Why?
|
| Skin | 1 | 2015 | 436 | 0.020 |
Why?
|
| Thymus Gland | 1 | 2012 | 241 | 0.020 |
Why?
|
| RNA, Long Noncoding | 1 | 2014 | 171 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2011 | 55 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2011 | 85 | 0.020 |
Why?
|
| Cadherins | 1 | 2011 | 90 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 559 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2014 | 793 | 0.020 |
Why?
|
| Phenotype | 1 | 2015 | 1236 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2011 | 267 | 0.020 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2010 | 5 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2011 | 153 | 0.020 |
Why?
|
| Calcium | 1 | 2014 | 587 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 1502 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 366 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2014 | 1161 | 0.020 |
Why?
|
| DNA Repair | 1 | 2011 | 263 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1635 | 0.020 |
Why?
|
| MRE11 Homologue Protein | 1 | 2009 | 8 | 0.020 |
Why?
|
| A Kinase Anchor Proteins | 1 | 2008 | 5 | 0.020 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2009 | 37 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2008 | 38 | 0.020 |
Why?
|
| Wills | 1 | 2008 | 1 | 0.020 |
Why?
|
| Chromosomes, Human | 1 | 2008 | 52 | 0.020 |
Why?
|
| Endogenous Retroviruses | 1 | 2008 | 12 | 0.020 |
Why?
|
| Mosaicism | 1 | 2008 | 29 | 0.020 |
Why?
|
| Histones | 1 | 2011 | 497 | 0.020 |
Why?
|
| Proviruses | 1 | 2008 | 27 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2013 | 829 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2008 | 326 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 277 | 0.020 |
Why?
|
| Word Association Tests | 1 | 2005 | 4 | 0.010 |
Why?
|
| Wechsler Scales | 1 | 2005 | 16 | 0.010 |
Why?
|
| Verbal Learning | 1 | 2005 | 21 | 0.010 |
Why?
|
| Orientation | 1 | 2005 | 26 | 0.010 |
Why?
|
| Problem Solving | 1 | 2005 | 32 | 0.010 |
Why?
|
| Intelligence | 1 | 2005 | 51 | 0.010 |
Why?
|
| Genetic Techniques | 1 | 2005 | 39 | 0.010 |
Why?
|
| Mental Recall | 1 | 2005 | 95 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 330 | 0.010 |
Why?
|
| Multigene Family | 1 | 2005 | 106 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2005 | 139 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2009 | 719 | 0.010 |
Why?
|
| beta-Transducin Repeat-Containing Proteins | 1 | 2003 | 5 | 0.010 |
Why?
|
| SMARCB1 Protein | 1 | 2003 | 13 | 0.010 |
Why?
|
| Promyelocytic Leukemia Protein | 1 | 2003 | 14 | 0.010 |
Why?
|
| Information Storage and Retrieval | 1 | 2004 | 60 | 0.010 |
Why?
|
| Cyclophilin A | 1 | 2003 | 34 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2003 | 124 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2003 | 42 | 0.010 |
Why?
|
| Psychometrics | 1 | 2005 | 396 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2006 | 414 | 0.010 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2003 | 61 | 0.010 |
Why?
|
| GTP-Binding Proteins | 1 | 2003 | 93 | 0.010 |
Why?
|
| Pseudogenes | 1 | 2002 | 12 | 0.010 |
Why?
|
| Epithelium | 1 | 2003 | 100 | 0.010 |
Why?
|
| Exons | 1 | 2004 | 208 | 0.010 |
Why?
|
| Genes | 1 | 2002 | 90 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2002 | 103 | 0.010 |
Why?
|
| Rabbits | 1 | 2002 | 342 | 0.010 |
Why?
|
| RNA, Untranslated | 1 | 2002 | 105 | 0.010 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2003 | 184 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2003 | 220 | 0.010 |
Why?
|
| Prognosis | 1 | 2006 | 1793 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 5681 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 367 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2003 | 1561 | 0.010 |
Why?
|